<DOC>
	<DOCNO>NCT01968382</DOCNO>
	<brief_summary>Hypothesis : Oral administration hyperimmune bovine colostrum enrich anti-LPS antibody reduce endotoxemia , improve pathophysiological clinical parameter relate severe alcoholic hepatitis ( SAH ) . IMM 124-E safe subject severe alcoholic hepatitis treat steroid . Aim : To perform phase 2a `` proof concept '' placebo-controlled , dose-ranging study Imm 124-E ( hyperimmune bovine colostrum enrich IgG anti-LPS ) subject severe AH steroid .</brief_summary>
	<brief_title>Safety Efficacy IMM 124-E Patients With Severe Alcoholic Hepatitis</brief_title>
	<detailed_description>Subjects severe alcoholic hepatitis ( 20= &gt; MELD &lt; =28 ) receive prednisolone ( 40 mg/day x 28 day ) randomize 1:1:1 additionally receive either one two dos IMM 124-E ( 2400 mg/day 4800 mg/day ) orally placebo duration . Standard care nutrition support alcohol cessation recommendation provide subject . Alcohol withdrawal manage per standard care . Subjects meet Lille criterion failure treatment day 7 side effect require discontinuation steroid remove study . The primary endpoint decrease plasma endotoxin level . The secondary endpoint include : 1 . Mechanistic endpoint : TNF-Î± , immune-inflammatory marker , microbiome-metagenome 2 . Efficacy-related : number subject meet Lille failure criterion day 7 , mortality ( 30 day , 90 day , 180 day ) , time drop conjugate bilirubin 50 % , bile acid , liver function test , change MELD , sequential organ failure 3 . Safety relate : tolerability , adverse event .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Alcoholic</mesh_term>
	<criteria>Alcoholic hepatitis Men woman age 21 MELD &gt; = 20 &lt; =28 About initiate prednisolone treatment , &lt; 7 day steroid treatment , treatment naive . Actively consume alcohol within 6 week entry study Willing able comply study requirement ( include contraception ) Subjects legally authorize representative ( LAR ) provide voluntary write informed consent . Failure obtain informed consent Subjects know HIV positive Active infection sepsis ( pneumonia Xray , positive blood urine culture ) multiorgan failure Other concomitant liver disease present : viral hepatitis , autoimmune liver disease , metabolic liver disease , vascular liver disease Cow milk allergy severe lactose intolerance Active GI bleeding Untreated spontaneous bacterial peritonitis base &gt; 250 polymorphonuclear cell positive culture Acute kidney injury time randomization Creatinine &gt; 1.5 md/dL Evidence acute pancreatitis ( image lipase ) biliary obstruction ( dilate bile duct ) Subjects pregnant lactate Significant systemic major illness , , opinion Investigator would preclude patient participate complete study Patients require use vasopressor inotropic support 12 hour prior randomization Treatment alcoholic hepatitis within 1 month study entry corticosteroid use &gt; 1 week immediately prior time entry study . Any patient receive investigational drug device within 30 day dose scheduled receive another investigational drug device course study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>IMM 124-E</keyword>
	<keyword>Bovine Colostrum</keyword>
	<keyword>Alcoholic</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>LPS</keyword>
	<keyword>Hyper-immune</keyword>
</DOC>